Advertisement


Robert Olson, MD, on Quality-of-Life Outcomes After Stereotactic Ablative Radiotherapy vs Standard-of-Care Palliative Treatments

2019 ASTRO Annual Meeting

Advertisement

Robert Olson, MD, of the BC Cancer Centre for the North, discusses a secondary analysis of the SABR-COMET trial, which showed there was a small magnitude decline in quality of life in both arms of the study but no associated detriment with stereotactic ablative radiotherapy (Abstract 148).



Related Videos

Head and Neck Cancer

David Routman, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV Circulating Tumor DNA

David Routman, MD, of the Mayo Clinic, discusses his study findings showing that detectable human papillomavirus circulating tumor DNA in the postoperative setting may be lin...

Issues in Oncology
Solid Tumors

Daniel M. Trifiletti, MD, on Optimizing Whole-Brain Radiotherapy Dose and Fractionation for Patients With Brain Metastases

Daniel M. Trifiletti, MD, of the Mayo Clinic, discusses study findings showing that, between two different radiation doses (30 Gy/10 fractions vs 37.5 Gy/15 fractions), there...

Prostate Cancer

Ryan Phillips, MD, PhD, on Oligometastatic Prostate Cancer: ORIOLE Trial on Observation vs Stereotactic Ablative Radiation

Ryan Phillips, MD, PhD, of Johns Hopkins Medical Institutions, discusses phase II findings suggesting that treatment with stereotactic ablative radiation significantly decrea...

Solid Tumors
Colorectal Cancer

Alejandra Méndez Romero, MD, PhD, on Liver Metastases: Dutch-Belgian Registry of Stereotactic Body Radiation

Alejandra Méndez Romero, MD, PhD, of Erasmus University Medical Center, discusses findings that show high local control rates with stereotactic body radiation for patients in...

Prostate Cancer

Daniel E. Spratt, MD, on the Impact of Antiandrogen Treatment in Prostate Cancer: NRG Oncology/RTOG 9601 Trial

Daniel E. Spratt, MD, of the University of Michigan, discusses phase III study findings showing that 2 years of antiandrogen therapy increased cardiac and neurologic toxiciti...

Advertisement

Advertisement



Advertisement